"Fluorouracil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
| Descriptor ID |
D005472
|
| MeSH Number(s) |
D03.383.742.698.875.404
|
| Concept/Terms |
Fluorouracil- Fluorouracil
- 5FU
- 5-FU
- 5-Fluorouracil
- 5 Fluorouracil
- Fluoruracil
Efudix- Efudix
- Fluoro-Uracile ICN
- Fluoro Uracile ICN
- Efudex
|
Below are MeSH descriptors whose meaning is more general than "Fluorouracil".
Below are MeSH descriptors whose meaning is more specific than "Fluorouracil".
This graph shows the total number of publications written about "Fluorouracil" by people in this website by year, and whether "Fluorouracil" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 4 | 5 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 1 | 2 | 3 |
| 2004 | 1 | 1 | 2 |
| 2005 | 3 | 4 | 7 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 3 | 4 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 6 | 7 |
| 2010 | 1 | 4 | 5 |
| 2011 | 0 | 1 | 1 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 7 | 8 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 4 | 5 |
| 2017 | 0 | 3 | 3 |
| 2018 | 2 | 3 | 5 |
| 2019 | 1 | 4 | 5 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 3 | 3 |
| 2024 | 3 | 2 | 5 |
| 2025 | 1 | 4 | 5 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluorouracil" by people in Profiles.
-
Topical combined 5-fluorouracil and calcipotriene for actinic keratosis and superficial keratinocyte carcinoma: Modified Delphi expert panel recommendations from ITSCC. J Am Acad Dermatol. 2026 Jul; 95(1):112-120.
-
AquIRE reveals the mechanisms of clinically induced RNA damage and the conservation and dynamics of glycoRNAs. Nucleic Acids Res. 2026 Feb 05; 54(4).
-
Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II Trial. Ann Surg Oncol. 2026 Apr; 33(4):2899-2907.
-
Overall Survival for Bevacizumab Therapy in Metastatic Colorectal Cancer: An Updated Analysis of the TRAVASTIN Study. Clin Colorectal Cancer. 2026 03; 25(1):115-124.
-
Physiological Level of Eosinophils Is Essential for the Regeneration and Homeostasis of Murine Hematopoietic Stem Cells. Allergy. 2026 May; 81(5):1749-1762.
-
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. Cell Rep Med. 2025 Apr 15; 6(4):102053.
-
Advanced-stage duodenal cancer in pregnancy. BMJ Case Rep. 2025 Jan 09; 18(1).
-
Ribosome Quality Control mitigates the cytotoxicity of ribosome collisions induced by 5-Fluorouracil. Nucleic Acids Res. 2024 11 11; 52(20):12534-12548.
-
HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 study. Cancer Commun (Lond). 2024 Dec; 44(12):1431-1443.
-
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clin Colorectal Cancer. 2024 06; 23(2):183-193.